DNMT3A mutational status affects the results of dose-escalated induction therapy in acute myelogenous leukemia Academic Article uri icon

Overview

MeSH Major

  • DNA (Cytosine-5-)-Methyltransferase
  • Induction Chemotherapy
  • Leukemia, Myeloid, Acute

abstract

  • Patients with DNMT3A-mutated AML have an inferior survival when treated with standard-dose anthracycline induction therapy. This group should be considered for high-dose induction therapy.

publication date

  • April 2015

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC4383675

Digital Object Identifier (DOI)

  • 10.1158/1078-0432.CCR-14-0327

PubMed ID

  • 25609058

Additional Document Info

start page

  • 1614

end page

  • 20

volume

  • 21

number

  • 7